Grifols To Divest Factor VIII Product Koate To Merge With Talecris
This article was originally published in The Pink Sheet Daily
Executive Summary
Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.
You may also be interested in...
Analysts Mixed As Australia’s CSL Moves To Settle U.S. Price Fixing Case
Australia’s CSL has probably made the right decision to settle a price-fixing lawsuit in the United States and thereby avoid a protracted legal battle that could have seen further substantial legal costs even if it eventually won. But the proposed settlement has some analysts concerned the legal basis for the lawsuit was thin as it stemmed from regulatory questions raised in a failed industry merger.
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.